PE20000952A1 - Derivados de glicol xantinas - Google Patents

Derivados de glicol xantinas

Info

Publication number
PE20000952A1
PE20000952A1 PE1999000814A PE00081499A PE20000952A1 PE 20000952 A1 PE20000952 A1 PE 20000952A1 PE 1999000814 A PE1999000814 A PE 1999000814A PE 00081499 A PE00081499 A PE 00081499A PE 20000952 A1 PE20000952 A1 PE 20000952A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
xanthines
methyl
cinamic
Prior art date
Application number
PE1999000814A
Other languages
English (en)
Spanish (es)
Inventor
Susan Mary Daluge
Jurgensen Cynthia Holder
Michael Tolar Martin
Martin Howard Osterhout
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20000952A1 publication Critical patent/PE20000952A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1999000814A 1998-08-13 1999-08-11 Derivados de glicol xantinas PE20000952A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PE20000952A1 true PE20000952A1 (es) 2000-09-29

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000814A PE20000952A1 (es) 1998-08-13 1999-08-11 Derivados de glicol xantinas

Country Status (36)

Country Link
US (3) US6608069B1 (enExample)
EP (1) EP1104422B1 (enExample)
JP (3) JP3631961B2 (enExample)
KR (1) KR20010085369A (enExample)
CN (2) CN1251676C (enExample)
AP (1) AP1408A (enExample)
AR (1) AR020154A1 (enExample)
AT (1) ATE259810T1 (enExample)
AU (1) AU775819B2 (enExample)
BR (1) BR9913020A (enExample)
CA (1) CA2340350A1 (enExample)
CO (1) CO5130007A1 (enExample)
DE (1) DE69914921T2 (enExample)
DK (1) DK1104422T3 (enExample)
EA (1) EA004139B1 (enExample)
EE (1) EE04721B1 (enExample)
ES (1) ES2215399T3 (enExample)
GB (1) GB9817623D0 (enExample)
HU (1) HUP0103637A3 (enExample)
ID (1) ID28723A (enExample)
IL (1) IL141318A0 (enExample)
IS (1) IS5843A (enExample)
MA (1) MA26673A1 (enExample)
MY (1) MY133393A (enExample)
NO (1) NO20010715L (enExample)
NZ (1) NZ509778A (enExample)
PE (1) PE20000952A1 (enExample)
PL (1) PL346055A1 (enExample)
PT (1) PT1104422E (enExample)
SI (1) SI1104422T1 (enExample)
SK (1) SK2222001A3 (enExample)
TR (1) TR200100448T2 (enExample)
TW (1) TWI224598B (enExample)
WO (1) WO2000009507A1 (enExample)
YU (1) YU11601A (enExample)
ZA (1) ZA200101186B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2428753C (en) * 2000-11-17 2013-05-21 Universita Degli Studi Di Cagliari Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
JP2004523559A (ja) * 2001-02-28 2004-08-05 スミスクライン ビーチャム コーポレーション 過敏性腸症候群および機能性胃腸症の治療方法
WO2003017964A1 (en) 2001-08-24 2003-03-06 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR100937620B1 (ko) 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 A2b 아데노신 수용체 길항제
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
NZ545715A (en) * 2003-08-25 2009-02-28 Adenosine Therapeutics Llc Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006091936A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US8318728B2 (en) 2008-05-14 2012-11-27 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN105358155A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015417A (es) * 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CN120435477A (zh) 2022-12-20 2025-08-05 英威欧斯有限公司 被取代的3,7-二氢-1h-嘌呤-2,6-二酮及其用途
EP4389749A1 (en) * 2022-12-20 2024-06-26 invIOs GmbH Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (enExample) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
EP0728017A1 (en) * 1993-11-10 1996-08-28 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
AU2213697A (en) 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
ATE226583T1 (de) 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO1999043673A1 (en) 1998-02-26 1999-09-02 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
ATE259810T1 (de) 2004-03-15
CN1149215C (zh) 2004-05-12
TR200100448T2 (tr) 2001-09-21
SK2222001A3 (en) 2001-12-03
CN1323309A (zh) 2001-11-21
DE69914921T2 (de) 2004-12-23
IS5843A (is) 2001-02-09
PL346055A1 (en) 2002-01-14
ZA200101186B (en) 2002-02-12
AR020154A1 (es) 2002-04-10
TWI224598B (en) 2004-12-01
EE200100083A (et) 2002-06-17
CN1515571A (zh) 2004-07-28
EE04721B1 (et) 2006-10-16
EA004139B1 (ru) 2004-02-26
JP2004137251A (ja) 2004-05-13
PT1104422E (pt) 2004-06-30
JP2004115534A (ja) 2004-04-15
IL141318A0 (en) 2002-03-10
SI1104422T1 (en) 2004-06-30
NO20010715L (no) 2001-04-02
MA26673A1 (fr) 2004-12-20
CA2340350A1 (en) 2000-02-24
ES2215399T3 (es) 2004-10-01
HUP0103637A2 (en) 2002-06-29
CO5130007A1 (es) 2002-02-27
EA200100127A1 (ru) 2001-10-22
HUP0103637A3 (en) 2002-10-28
MY133393A (en) 2007-11-30
US20040034020A1 (en) 2004-02-19
AU775819B2 (en) 2004-08-19
NZ509778A (en) 2003-08-29
AP2001002071A0 (en) 2001-03-31
WO2000009507A1 (en) 2000-02-24
HK1035195A1 (en) 2001-11-16
EP1104422B1 (en) 2004-02-18
JP3631961B2 (ja) 2005-03-23
JP2002522542A (ja) 2002-07-23
US20030032804A1 (en) 2003-02-13
DK1104422T3 (da) 2004-06-14
AU5732399A (en) 2000-03-06
US6770267B2 (en) 2004-08-03
NO20010715D0 (no) 2001-02-12
CN1251676C (zh) 2006-04-19
GB9817623D0 (en) 1998-10-07
DE69914921D1 (en) 2004-03-25
AP1408A (en) 2005-05-06
BR9913020A (pt) 2001-05-08
YU11601A (sh) 2004-03-12
KR20010085369A (ko) 2001-09-07
ID28723A (id) 2001-06-28
US6608069B1 (en) 2003-08-19
EP1104422A1 (en) 2001-06-06

Similar Documents

Publication Publication Date Title
NZ503794A (en) Benzimidazole and imidazopyridine derived heterocyclic compounds, pharmaceutical compositions and uses thereof
JP2007511527A5 (enExample)
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
DK155737C (da) Analogifremgangsmaade til fremstilling af n-phenylethanolaminoalkyl-substituerede nitrogenholdige heterocycliske forbindelser eller syreadditionssalte deraf
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
DE69923692D1 (de) Wachstumshormon-freisetzende oxindolderivate
KR870004042A (ko) 실란 유도체의 제조방법
ATE90107T1 (de) Peptide mit collagenase hemmender wirkung.
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
SE0101579D0 (sv) New compounds
YU12992A (sh) 2-amino-1,2,3,4,-tetrahidronaftaleni supstituisani u prstenu
PE58899A1 (es) Esteres y amidas de fenil xantina
PE20050160A1 (es) 3-aminopirrolidinas como inhibidores de la captacion de monoaminas
ES2058531T3 (es) Amidas de mercapto-fenilalcanoilaminoacidos, su preparacion y su uso como inhibidores de colagenasa.
ES466366A1 (es) Un procedimiento para preparar derivados de metasulfonamido-benzamida.
FI814148L (fi) Nya trisubstituerade pyrimido/5,4-d/pyrimidiner deras framstaellning och deras anvaendning saosom laekemedel
DK0492178T3 (da) Naphthoesyre-derivat
EA200001165A1 (ru) Производные тетрагидрохинолина в качестве антагонистов глицина
GB1048086A (en) Polypeptide derivatives
FI894783A0 (fi) Substituerade aromatiska foereningar med verkan pao det centrala nervsystemet.
CY1110038T1 (el) 4-(διαρυλομεθυλ)-1- πιπεραζινυλ παραγωγα
DK0475364T3 (da) Diamino-s-triazinonderivater
EA199901034A3 (ru) Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы
EP1056700A4 (en) MEDICAL APPLICATIONS OF PHENYL ALCOHOLS AND DERIVATIVES THEREOF

Legal Events

Date Code Title Description
FD Application declared void or lapsed